Trial · NCT00288704
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A, Double Blind, Weeks 1-6 | STARTED | Placebo | 24 | |
| Part A, Double Blind, Weeks 1-6 | STARTED | Rilonacept 160 mg | 23 | |
| Part A, Double Blind, Weeks 1-6 | STARTED | Open-Label Extension (OLE) Rilonacept 160 mg | 0 | |
| Part A, Double Blind, Weeks 1-6 | COMPLETED | Placebo | 24 | |
| Part A, Double Blind, Weeks 1-6 | COMPLETED | Rilonacept 160 mg | 22 | |
| Part A, Double Blind, Weeks 1-6 | COMPLETED | Open-Label Extension (OLE) Rilonacept 160 mg | 0 | |
| Part A, Double Blind, Weeks 1-6 | NOT COMPLETED | Placebo | 0 | |
| Part A, Double Blind, Weeks 1-6 | NOT COMPLETED | Rilonacept 160 mg | 1 | |
| Part A, Double Blind, Weeks 1-6 | NOT COMPLETED | Open-Label Extension (OLE) Rilonacept 160 mg | 0 | |
| Part B, Randomized Withdrawal, Wks 15-24 | STARTED | Placebo | 23 | |
| Part B, Randomized Withdrawal, Wks 15-24 | STARTED | Rilonacept 160 mg | 22 | |
| Part B, Randomized Withdrawal, Wks 15-24 | STARTED | Open-Label Extension (OLE) Rilonacept 160 mg | 0 | |
| Part B, Randomized Withdrawal, Wks 15-24 | COMPLETED | Placebo | 23 | |
| Part B, Randomized Withdrawal, Wks 15-24 | COMPLETED | Rilonacept 160 mg | 21 | |
| Part B, Randomized Withdrawal, Wks 15-24 | COMPLETED | Open-Label Extension (OLE) Rilonacept 160 mg | 0 | |
| Part B, Randomized Withdrawal, Wks 15-24 | NOT COMPLETED | Placebo | 0 | |
| Part B, Randomized Withdrawal, Wks 15-24 | NOT COMPLETED | Rilonacept 160 mg | 1 | |
| Part B, Randomized Withdrawal, Wks 15-24 | NOT COMPLETED | Open-Label Extension (OLE) Rilonacept 160 mg | 0 | |
| Open-Label Extension (OLE) Weeks 24-117 | STARTED | Placebo | 0 | |
| Open-Label Extension (OLE) Weeks 24-117 | STARTED | Rilonacept 160 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00288704/flow